Streetbeat News

IMCC

IM Cannabis Corp.

https://www.imcannabis.com

Industry

Drug Manufacturers - Specialty & Generic

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel, Germany, and Canada. It offers cannabis flowers and strain specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, and pressed hash offerings under the WAGNERS and Highland Grow brands. The company serves medical patients and adult-use recreational consumers. IM Cannabis Corp. is headquartered in Tel Aviv-Yafo, Israel.

Open

2.81

Mkt cap

6.7M

Volume

11K

High

3.00

P/E Ratio

-0.66

52-wk high

8.10

Low

2.81

Div yield

N/A

52-wk low

1.13

IM Cannabis Corp. (NASDAQ:IMCC) held its Q3 2024 earnings conference call on November 14, 2024. Key participants included Anna Taranko, Oren Shuster, and Uri Birenberg.

Portfolio Pulse from

November 14, 2024 | 4:00 pm

A legislative committee in Ireland has recommended the limited legalization of marijuana and the decriminalization of all illicit drugs for personal use. The report emphasizes a health-led approach to drug policy, aiming to reduce harm and stigma. The committee suggests studying regulated cannabis markets in other countries and expanding Ireland's medical marijuana program.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 7:26 pm

The cannabis industry is experiencing significant leadership changes. Notable updates include Aurora Cannabis Inc.'s CEO Miguel Martin taking on the role of executive chairman, and IM Cannabis Corp. appointing Shmulik Arbel to its board. Canopy Growth Corporation's shareholders confirmed their board nominees, and Flora Growth Corp. named Harold Wolkin as an independent director. These changes reflect ongoing shifts in the cannabis sector's leadership landscape.

Portfolio Pulse from Jelena Martinovic

October 11, 2024 | 1:26 am

IM Cannabis Corp. (NASDAQ:IMCC) is undertaking a $1.6M non-brokered private placement offering to repay a loan. The offering includes shares and warrants, with a closing expected by Nov. 11, 2024. Recent strategic moves include a share consolidation and strong financial performance, particularly in Germany.

Portfolio Pulse from Jelena Martinovic

October 04, 2024 | 5:09 pm

Spain's Ministry of Health has released a draft royal decree for public consultation, outlining regulations for prescribing cannabis-based medications. This follows a delay due to a government change. Meanwhile, IM Cannabis Corp. reported a 50% revenue increase in Germany, attributed to partial cannabis legalization.

Portfolio Pulse from Jelena Martinovic

October 03, 2024 | 3:18 am

IM Cannabis Corp. (NASDAQ:IMCC) reported a 50% increase in Q3 2024 revenue for its German subsidiary, IMC Germany, compared to Q2. This growth highlights successful strategic initiatives and strong market demand.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 12:11 pm

Lawmakers are pressing the DEA to finalize a proposal to reschedule marijuana, which could impact the cannabis industry and related stocks.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 3:44 pm

Cannabis stocks are experiencing a surge in trading following a report that Vice President Harris is advocating for the legalization of marijuana.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 3:16 pm

The DEA is proposing significant increases in production quotas for marijuana compounds and psychedelics like psilocybin and ibogaine to support research and clinical trials. This move reflects growing interest in these substances for medical and scientific purposes.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 5:41 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.